GSK Buys Proteomics Company

May 16, 2012

May 16, 2012 | GlaxoSmithKline has purchased the remaining percentage of Cellzome for about $98 million in cash. The pharma already owns 80.02% of Cellzome, a drug discovery company with proteomics technologies that can be used to screen and profiles compounds in cells and patient samples. Fox Business